about
Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaksStrategies to Prevent Cholera Introduction during International Personnel Deployments: A Computational Modeling Analysis Based on the 2010 Haiti OutbreakCholera outbreak in districts around Lake Chilwa, Malawi: lessons learnedGenetically modified organisms and visceral leishmaniasisCosts of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in MicLocal perceptions of cholera and anticipated vaccine acceptance in Katanga province, Democratic Republic of Congo.Vaccines in the time of cholera.Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.Improving community coverage of oral cholera mass vaccination campaigns: lessons learned in Zanzibar.Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.Modeling the effect of water, sanitation, and hygiene and oral cholera vaccine implementation in Haiti.Cholera vaccination in urban Haiti.Vaccination of travelers: how far have we come and where are we going?New-generation vaccines against cholera.Business travelers: vaccination considerations for this population.Vaccination for the expatriate and long-term traveler.Challenges in mucosal vaccines for the control of infectious diseases.Vaccine-preventable travel health risks: what is the evidence--what are the gaps?Social and cultural determinants of anticipated acceptance of an oral cholera vaccine prior to a mass vaccination campaign in Zanzibar.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Insights from natural infection-derived immunity to cholera instruct vaccine efforts.Guinea pig complement potently measures vibriocidal activity of human antibodies in response to cholera vaccines.The Euvichol story - Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships
P2860
Q21090119-82BEF2B5-644F-4FFC-B6FA-18AF2BB6F6E4Q28552894-1B9D35F6-6806-4B25-A50F-490EAD3C7940Q30223057-239A5F66-7CE1-4F8D-A0F7-74C01E356916Q33647026-823D90CE-2141-450E-888C-0A77D1280440Q34305452-F0910C5E-03C3-4A1D-A54A-EDA12736BF09Q34334260-C1D8AD5B-7B71-445C-BCA7-8DF61A3D83A6Q34484003-165AE814-76EE-49D8-895A-219844FCEEE4Q34557237-695120AF-A77F-49B6-8E81-BF72DA3618A6Q35008404-482DBBEF-D096-4CC3-B333-BA452E0C5FFDQ35867213-9DB90451-70B1-447F-9880-3D8E7B967C7CQ35940653-EF168A7B-5FCC-4E18-8529-CDDE7C3DCFD5Q36109512-954185CC-3B8D-442A-A92D-041D8D2DA27AQ36431001-808FEB6E-FEE2-4C02-8143-F3615781D9BEQ36970778-8DFA7F6B-3506-40F3-BEA5-4325FFE47E72Q37225744-FA11B179-A2AB-43D1-884A-FAA02DB68226Q37225765-B4CED3E9-A74F-4D9B-B65E-51C6FE3714EEQ37951528-3696373D-4C01-43FE-A153-170B0FA0139FQ37953796-BCD2A0A9-E247-4807-A019-B086394D08DFQ38096494-A80F5779-D37C-4A45-9ACF-5B4A3F8B79E7Q38208436-BDA9A838-85E9-44D7-A7A7-E6B159E1CE13Q38219010-BA1CF47D-D67E-4EE7-8087-9545B395901BQ38265969-27CA296E-3468-491F-B528-B326AD6C154FQ39434930-2C19D857-88F8-463B-A24E-8E307907915BQ40560650-3B38D776-C248-4025-9A19-B5227BD912D5Q41426133-18ADE67B-978A-4D6E-BA04-F5F1E4E31656Q46246286-54CE1F7B-B144-452F-8FC3-F010D7EA4355Q57481187-8AD675CC-7F65-46AC-807B-BC5700508B40
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Oral vaccines against cholera.
@ast
Oral vaccines against cholera.
@en
type
label
Oral vaccines against cholera.
@ast
Oral vaccines against cholera.
@en
prefLabel
Oral vaccines against cholera.
@ast
Oral vaccines against cholera.
@en
P2093
P2860
P356
P1476
Oral vaccines against cholera.
@en
P2093
Binod K Sah
John D Clemens
Sachin N Desai
Sunheang Shin
P2860
P304
P356
10.1093/CID/CIR141
P407
P577
2011-04-14T00:00:00Z